Drug-Associated Renal Dysfunction

Critical Care Clinics

Volumn 22, Issue 2, 2006, Pages 357-374

  Taber, Stephanie S ^a   Mueller, Bruce A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ADRENALIN; ALLOPURINOL; AMINOGLYCOSIDE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; AZATHIOPRINE; AZTREONAM; BACITRACIN; CAPTOPRIL; CARBAMAZEPINE; CEFAZOLIN; CEFEPIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COCODAMOL; CYCLOSPORIN; DOPAMINE; FUROSEMIDE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLIN DERIVATIVE; SULTAMICILLIN; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ALLERGY; ARTHRALGIA; CHILD; CHOLESTEROL EMBOLISM; DRUG INDUCED DISEASE; ENZYMURIA; EOSINOPHILIA; FEVER; GLOMERULOPATHY; HEART ARRHYTHMIA; HUMAN; INTENSIVE CARE UNIT; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY PAPILLA NECROSIS; KIDNEY PERFUSION; KIDNEY TUBULE NECROSIS; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; NAUSEA; NECROSIS; NEPHROLITHIASIS; NEPHROSIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; OLIGURIA; PRIORITY JOURNAL; PROTEINURIA; PYURIA; RASH; REVIEW; SEPSIS; TUMOR LYSIS SYNDROME; VOMITING; CHEMICALLY INDUCED DISORDER; DRUG THERAPY; DRUG UTILIZATION; INTENSIVE CARE; NEWBORN; STATISTICS; UNITED STATES;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CRITICAL CARE; DRUG THERAPY; DRUG UTILIZATION; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS; KIDNEY DISEASES; MICHIGAN;

EID: 33745507481     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2006.02.003     Document Type: Review

References (56)

1. Uchino S., Kellum J.A., Bellomo R., et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294 7 (2005) 813-818
2. Ympa Y.P., Sakr Y., Reinhart K., et al. Has mortality from acute renal failure decreased? A systematic review of the literature. Am J Med 118 (2005) 827-832
3. Novis B.K., Roizen M.F., Aronson S., et al. Association of preoperative risk factors with postoperative acute renal failure. Anesth Analg 78 1 (1994) 143-149
4. Bernieh B., Al Hakim M., Boobes Y., et al. Pattern of acute renal failure in a tertiary hospital in the United Arab Emirates. Transplant Proc 36 6 (2004) 1780-1783
5. Micromedex® Healthcare Series. Greenwood Village (CO): Thomson Micromedex (edition expires [3/2006])
6. Bhatt-Mehta V., Schumacher R.E., Faix R.G., et al. Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study. Pediatrics 103 4 (1999) e48
7. Hock R., and Anderson R.J. Prevention of drug-induced nephrotoxicity in the intensive care unit. J Crit Care 10 1 (1995) 33-43
8. Perazella M.A. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med 325 (2003) 349-362
9. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 106 5B (1999) 13S-24S
10. Ahmad S.R., Kortepeter C., Brinker A., et al. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 25 7 (2002) 537-544
11. Morales E., and Mucksavage J.J. Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature. Pharmacother 22 10 (2002) 1317-1321
12. Perazella M.A., and Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 111 (2001) 64-67
13. Gambaro G., and Perazella M.A. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Int Med 253 (2003) 643-652
14. Harper L., and Savage C.O.S. The use of dopamine in acute renal failure. Clin Nephrol 47 (1997) 347-349
15. Richer M., Robert S., and Lebel M. Renal hemodynamics during norepinephrine and low-dose dopamine infusion in man. Crit Care Med 24 (1996) 1150-1156
16. Schaer G.L., Fink M.P., and Parrillo J.E. Norepinephrine alone versus norepinephrine plus low-dose dopamine: enhanced renal blood flow with combination vasopressor therapy. Crit Care Med 13 (1985) 492-496
17. Power D.A., Duggan J., and Brady H.R. Renal-dose (low-dose) dopamine for the treatment of sepsis-related and other forms of acute renal failure: ineffective and probably dangerous. Clin Exp Pharmacol Physiol Suppl 26 (1999) S23-S28
18. Chertow G.M., Sayegh M.H., Allgren R.L., et al. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure?. Am J Med 101 (1996) 49-53
19. Marik P.E., and Iglesias J. Low-dose dopamine does not prevent acute renal failure in patients with septic shock and oliguria. NORASEPT II Study Investigators. Am J Med 107 (1999) 387-390
20. Argalious M., Motta P., Khandwala F., et al. "Renal dose" dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery. Crit Care Med 33 6 (2005) 1327-1332
21. Bailey A.R., and Burchett K.R. Effect of low-dose dopamine on serum concentrations of prolactin in critically ill patients. Br J Anaesth 78 (1997) 97-99
22. Mingeot-Leclercq M.P., and Tulkens P.M. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 43 5 (1999) 1003-1012
23. Swan S.K. Aminoglycoside nephrotoxicity. Semin Nephrol 17 (1997) 27-33
24. Fanos V., and Cataldi L. Renal transport of antibiotics and nephrotoxicity: a review. J Chemother 13 5 (2001) 461-472
25. Nagai J., and Takan M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet 19 3 (2004) 159-170
26. Olsen K.M., Rudis M.I., Rebuck J.A., et al. Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med 32 8 (2004) 1678-1682
27. Joannidis M. Drug-induced renal failure in the ICU. Int J Artif Org 27 12 (2004) 1034-1042
28. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 49 Suppl S1 (2002) 37-41
29. Tiphine M., Letscher-Bru V., and Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis 1 (1999) 273-283
30. Anderson C.M. Sodium chloride treatment of amphotericin B nephrotoxicity-standard of care?. West J Med 162 4 (1995) 313-317
31. Sharkey P.K., Graybill J.R., Johnson E.S., et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 22 2 (1996) 315-321
32. Walsh T.J., Finberg R.W., Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340 10 (1999) 764-771
33. White M.H., Bowden R.A., Sandler R.A., et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27 2 (1998) 296-302
34. Goldenberg I., and Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventative strategies. CMAJ 172 11 (2005) 1461-1471
35. Iakovou I., Dangas G., Mehran R., et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 15 1 (2003) 18-22
36. McCullough P.A., Wolyn R., Rocher L.L., et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103 5 (1997) 368-375
37. Rihal C.S., Textor S.C., Grill D.E., et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105 19 (2002) 2259-2264
38. Barrett B.J., and Carlisle E.J. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 188 1 (1993) 171-178
39. Stevens M.A., McCullough P.A., Tobin K.J., et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol 33 2 (1999) 403-411
40. Merten G.J., Burgess W.P., Gray L.V., et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291 19 (2004) 2328-2334
41. Goldenberg I., Schechter M., Matetzky S., et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J 25 3 (2004) 212-218
42. Markowitz G.S., and Perazella M.A. Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta 351 (2005) 31-47
43. Michel D.M., and Kelly C.J. Acute interstitial nephritis. J Am Soc Nephrol 9 3 (1998) 506-515
44. Sakarcan A., Marcille R., and Stallworth J. Antibiotic-induced recurring interstitial nephritis. Pediatr Nephrol 17 (2002) 50-51
45. Toto R.D. Review: acute tubulointerstitial nephritis. Am J Med Sci 299 6 (1999) 392-410
46. Pill M.W., O'Neill C.V., Chapman M.M., et al. Suspected acute interstitial nephritis induced by piperacillin-tazobactam. Pharmacother 17 1 (1997) 166-169
47. Izzedine H., Launay-Vacher V., and Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45 5 (2005) 804-817
48. Perazella M.A. Crystal-induced acute renal failure. Am J Med 106 (1999) 459-465
49. Bean B., and Aeppli D. Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J Infect Dis 151 2 (1985) 362-365
50. Brigden D., Rosling A.E., and Woods N.C. Renal function after acyclovir intravenous injection. Am J Med 73 (1982) 182-185
51. Keeney R.E., Kirk L.E., and Bridgen D. Acyclovir tolerance in humans. Am J Med 73 (1982) 176-181
52. Krasny H.C., Liao S.H., deMiranda P., et al. Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. Am J Med 73 1A (1982) 202-204
53. Laskin O.L., Longstreth J.A., Whelton A., et al. Effect of renal failure on the pharmacokinetics of acyclovir. Am J Med 73 1A (1982) 197-201
54. Cairo M.S., and Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127 (2004) 3-11
55. Davidson M.B., Thakkar S., Hix J.K., et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116 (2005) 546-564
56. Lameire N.H., Flombaum C.S., Moreau D., et al. Acute renal failure in cancer patients. Ann Med 37 (2005) 13-25